{
    "organizations": [],
    "uuid": "49c6f1468f3d685e2ee242a81cc26fab42d8a2ac",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dermiras-two-phase-3-trials-evalua/brief-dermiras-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints-idUSASB0C8QQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Dermira Inc:\n* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS\n* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS\n* DERMIRA INC - COMPANY EXPECTS TO DISCONTINUE PROGRAM\n* DERMIRA - NONE OF THE CO-PRIMARY ENDPOINT RESULTS WERE STATISTICALLY SIGNIFICANT\n* DERMIRA - ‍ TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS AGES 9 YRS AND OLDER ​WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS\n* DERMIRA INC - ‍NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED, AND NO NEW OR UNEXPECTED EVENTS WERE OBSERVED​\n* DERMIRA - ‍CONSISTENT WITH PHASE 2A,2B STUDIES, OLUMACOSTAT GLASARETIL WAS WELL-TOLERATED WITH ADVERSE EVENTS PRIMARILY MILD OR MODERATE IN SEVERITY​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-05T21:06:00.000+02:00",
    "crawled": "2018-03-06T22:16:32.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "dermira",
        "inc",
        "dermira",
        "two",
        "phase",
        "trial",
        "evaluating",
        "olumacostat",
        "glasaretil",
        "patient",
        "acne",
        "vulgaris",
        "meet",
        "endpoint",
        "dermira",
        "two",
        "phase",
        "trial",
        "evaluating",
        "olumacostat",
        "glasaretil",
        "patient",
        "acne",
        "vulgaris",
        "meet",
        "endpoint",
        "dermira",
        "inc",
        "company",
        "expects",
        "discontinue",
        "program",
        "dermira",
        "none",
        "endpoint",
        "result",
        "statistically",
        "significant",
        "dermira",
        "two",
        "phase",
        "trial",
        "evaluating",
        "olumacostat",
        "glasaretil",
        "patient",
        "age",
        "yr",
        "older",
        "acne",
        "vulgaris",
        "meet",
        "endpoint",
        "dermira",
        "inc",
        "serious",
        "adverse",
        "event",
        "reported",
        "new",
        "unexpected",
        "event",
        "dermira",
        "phase",
        "study",
        "olumacostat",
        "glasaretil",
        "adverse",
        "event",
        "primarily",
        "mild",
        "moderate",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}